Allosteric coupling between PIP <sub>2</sub> and Ca <sup>2+</sup> binding sites gates TMEM16A channels
Abstract
TMEM16A channels conduct Ca 2+ -activated Cl − currents that underlie essential physiological processes including epithelial secretion, smooth muscle contraction, and sensory transduction. Channel activation requires both intracellular Ca 2+ and the signaling phospholipid phosphatidylinositol 4,5-bisphosphate (PIP 2 ), yet the molecular basis of this dual regulation has remained unclear. Using gating molecular-dynamics simulations and structure-guided electrophysiology, we show that PIP 2 and Ca 2+ cooperatively gate TMEM16A through an allosterically coupled electrostatic network centered on the α4 helix. Specific PIP 2 headgroup phosphate interactions are essential for coupling Ca 2+ binding to channel opening, while the PIP 2 acyl chains engage hydrophobic surfaces of the helix to stabilize the open conformation. Disrupting either component of this lipid–protein interface reduces apparent PIP 2 affinity and impairs activation, whereas long-chain PIP 2 fully restores wild-type activity. These interactions act in concert with Ca 2+ -dependent structural rearrangements that widen the conduction pathway and enable Cl − permeation. Our findings establish that both the headgroup phosphates and acyl chains of PIP 2 play indispensable and complementary roles in TMEM16A gating. This mechanism defines a cooperative lipid–ion activation process that provides a general framework for understanding phosphoinositide regulation of ion channels and offers opportunities for structure-based design of TMEM16A modulators.
Article Details
Journal Info
Proceedings of the National Academy of Sciences
National Academy of Sciences
Authors (10)
Jie Xu
Ana Santa-Cruz
Department of Pharmaceutical Sciences, Center for Drug Discovery, School of Pharmacy and Pharmaceutical Sciences, Bouve College of Health Science, Northeastern University
Aishwarya Chandrashekar
Department of Pharmaceutical Sciences, Center for Drug Discovery, School of Pharmacy and Pharmaceutical Sciences, Bouve College of Health Science, Northeastern University
Takeharu Kawano
Department of Pharmaceutical Sciences, Center for Drug Discovery, School of Pharmacy and Pharmaceutical Sciences, Bouve College of Health Science, Northeastern University
R. Charles Kissell
Department of Pharmaceutical Sciences, Center for Drug Discovery, School of Pharmacy and Pharmaceutical Sciences, Bouve College of Health Science, Northeastern University
Mehreen Zaka
Department of Pharmaceutical Sciences, Center for Drug Discovery, School of Pharmacy and Pharmaceutical Sciences, Bouve College of Health Science, Northeastern University
Zhe Zhang
Meng Cui
Department of Pharmaceutical Sciences, Center for Drug Discovery, School of Pharmacy and Pharmaceutical Sciences, Bouve College of Health Science, Northeastern University
Diomedes E. Logothetis
Department of Pharmaceutical Sciences, Center for Drug Discovery, School of Pharmacy and Pharmaceutical Sciences, Bouve College of Health Science, Northeastern University
Leigh D. Plant
Department of Pharmaceutical Sciences, Center for Drug Discovery, School of Pharmacy and Pharmaceutical Sciences, Bouve College of Health Science, Northeastern University